HealthCare Roundtable e-News – February 17, 2026

 

 

Top News

Roundtable Joins CAPPA in White House Meeting on Patent Litigation

On February 9, the Public Sector Healthcare Roundtable joined the Coalition Against Pharma Patent Abuse (CAPPA) in a meeting with the White House Economic Advisory Council on the topic of patent litigation reform. Extended periods of patent litigation between brand pharmaceuticals and generic manufacturers unnecessarily inflate the cost of health care to consumers and delays access to cheaper, clinically equivalent medications. The Roundtable looks forward to working with CAPPA and the Administration on this topic.

 

House Health Subcommittee Examines Drug Supply Chain and Affordability

On February 11, the House Energy and Commerce Health Subcommittee held a hearing titled “Lowering Health Care Costs for All Americans: An Examination of the Prescription Drug Supply Chain.” The hearing, chaired by Rep. Morgan Griffith (R-VA), brought together stakeholders from across the pharmaceutical supply chain—including manufacturers, pharmacy benefit managers (PBMs), wholesalers, group purchasing organizations (GPOs), employer representatives, community pharmacists, and policy experts—to examine drivers of prescription drug affordability. The discussion builds on prior committee work examining vertical integration, consolidation, and pricing practices within the drug market.

Republican members highlighted recent enactment of federal PBM reform legislation through the recent passage of the fiscal year 2026 Labor, Health and Human Services, Education and Related Agencies (LHHS) appropriations bill and emphasized concerns about opacity in the drug supply chain, the concentration of market power among the largest PBMs, and incentives tied to list prices. Chairman Griffith described the system as operating “as if in a black box” and underscored Congress’s interest in improving transparency and affordability across all supply chain entities. Members also referenced the launch of “TrumpRx,” a new direct-to-consumer pricing platform intended to help patients identify lower cash prices for common medications. Democratic members focused on preserving and expanding provisions enacted under the Inflation Reduction Act (IRA), including Medicare drug price negotiation and inflationary rebates. Ranking Member Diana DeGette (D-CO) and Ranking Member Frank Pallone (D-NJ) argued that negotiated prices are already generating savings for Medicare beneficiaries and cautioned against policies that would weaken negotiation authority or destabilize coverage markets. They also raised concerns about coverage losses and uncompensated care costs resulting from broader health policy changes.

Witness testimony reflected sharp disagreement over which actors bear primary responsibility for high drug prices. Manufacturer representatives emphasized intellectual property protections and alleged distortions caused by middlemen, particularly PBMs, while PBM representatives defended their role in negotiating discounts and lowering net costs for employers and taxpayers. Generic and biosimilar manufacturers highlighted patent thickets and formulary barriers that limit competition. The hearing signals continued bipartisan interest in supply chain reform, increased oversight of consolidation and vertical integration, and potential next-step legislation targeting competition, transparency, and reimbursement incentives across the pharmaceutical marketplace.


Administrative Action

Former HHS Secretaries Argue MA Reduces Medicare Spending, Countering Policymakers’ Claims

A broad coalition of national health insurance stakeholders sent a letter to Congressional Committee Leaders urging them to advance the Apples to Apples Comparison Act. Introduced by Representative Aaron Bean (R-FL-04), the Apples to Apples Comparison Act would require the Secretary of the Department of Health and Human Services (HHS) to update Medicare program expenditures data to support analysis and require the Medicare Payment Advisory Commission (MedPAC) to conduct an annual retrospective analysis of average expenditures of Medicare Advantage (MA) plans compared to traditional Medicare. The coalition argues the bill is necessary to appropriately account for differences in eligibility, benefits, and value to beneficiaries when comparing MA to traditional Medicare.

The next day, former Department of Health and Human Services (HHS) Secretary Donna Shalala (Clinton Administration) and Secretary Tommy G. Thompson (W. Bush Administration) penned an opinion piece for STAT, asserting that claims that MA has failed to reduce Medicare spending are inaccurate. In the piece, Dr. Shalala and Captain Thompson agree with the coalition that the calculation is flawed. They appreciated MedPAC’s revision to their overpayment calculation, while worrying that the approach does not go far enough. Additionally, they recognized that the Centers for Medicare and Medicaid Services (CMS) celebrates MA premium stability without discussing more concerning trends including fewer plan choices, restricted supplemental benefits, and higher out-of-pocket (OOP) costs. Dr. Shalala and Captain Thompson encouraged Congress to focus reforms on fundamental program stability while leveraging technology to improve patient outcomes and experiences.

 

FDA Takes Steps to Restrict GLP-1 API Use in Non-FDA-Approved Compounded Drugs

On February 5, 2026, Hims & Hers Health (commonly referred to as “Hims”) announced that it would offer consumers a lower-cost compounded version of Novo Nordisk’s glucagon-like peptide-1 (GLP-1) weight loss pill, Wegovy – the first oral GLP-1 approved by the Food and Drug Administration (FDA). Hims’s version would be priced at $49 for the first month and $99 afterwards, $100 less than Novo’s Wegovy pill. Novo Nordisk responded that the compounding was illegal and indicated that the company would pursue legal and regulatory action to protect patients, its intellectual property and the FDA approval framework.”

Federal officials moved quickly to increase scrutiny. The Department of Health and Human Services (HHS) almost immediately referred Hims & Hers to the Department of Justice for potential violations of the FDA’s governing statute, while the FDA simultaneously announced its intent to restrict the use of GLP-1 active pharmaceutical ingredients (APIs) in non-FDA-approved compounded products. The FDA clarified that they cannot verify the quality, safety, or efficacy of the compounded drugs as generic equivalents to the brand-name GLP-1 products, stating the pending action is designed to promote consumer safety. The FDA reiterated its ongoing efforts to curb misleading direct-to-consumer advertising related to compounded drugs, building on its September 2025 “Crackdown on Deceptive Drug Advertising.” This initiative aims to enforce existing law to ensure pharmaceutical advertisements present a fair balance of benefits and drawbacks related to the advertised product.

Two days after the product launch, Hims & Hers announced their decision to discontinue offering the medication following discussions with industry partners, reaffirming their commitment to safe, affordable, personalized care. Although Novo Nordisk remains the only manufacturer with FDA approval for an oral GLP-1 medication, Eli Lily plans to submit their version to the FDA for approval in early 2026.

The FDA’s actions signal a broader effort to tighten oversight as GLP-1 supply stabilizes and additional branded therapies approach the market, potentially limiting the availability of compounded GLP-1 alternatives and increasing regulatory risk for telehealth platforms and compounding pharmacies competing on price or access.

 

CBO Releases Budget and Economic Outlook for 2026 to 2036

On February 11, 2026, the Congressional Budget Office (CBO) released its budget and economic outlook, which presents a 10-year projection covering deficits, the national debt, outlays and revenues, and inflation and interest rates, among other factors. Overall, CBO projects that the federal budget deficit will total $1.9 trillion in fiscal year (FY) 2026 and grow to $3.1 trillion by 2036. As part of this analysis, CBO also tracks spending on the major health care programs, including Medicare, Medicaid, and the Affordable Care Act (ACA). CBO projects that health care outlays will increase by nearly 5 percent in 2026 and continue to grow steadily, reaching $3.1 trillion, or 6.7 percent of GDP, by 2036. Medicare accounts for roughly three-quarters of the projected growth over the 2027–2036 period, driven by rising enrollment as the population ages and higher spending per beneficiary.

Medicare spending is projected to reach $1.1 trillion in 2026 and grow to $2.0 trillion by 2036, reflecting increased enrollment and average annual per-person spending growth of about 5 percent. Medicaid outlays are estimated to be $708 billion in 2026, with growth slowing in the near term due to changes enacted in the One Big Beautiful Bill Act (OBBBA), before accelerating again after 2029 as costs per enrollee and enrollment among older adults and people with disabilities increase. In contrast, spending on premium tax credits and related programs is projected to decline in 2026, largely because enhanced subsidies enacted during the pandemic expired at the end of 2025, reducing marketplace enrollment.


Congressional Action

Lawmakers Introduce Bipartisan Proposal to Limit Vertical Integration in Health Care

Senators Elizabeth Warren (D-MA) and Josh Hawley (R-MO) have introduced the Break Up Big Medicine Act, legislation aimed at limiting vertical integration across the health care system. Supporters argue that consolidation among insurers, pharmacy benefit managers (PBMs), drug wholesalers, and provider organizations has contributed to higher costs, reduced competition, and market pressures on independent physicians and pharmacies. Warren and Hawley argue that a small number of health insurers dominate key parts of the system, including PBMs and drug distribution, and many large companies operate across multiple points of the health care supply chain.

The bill would prohibit certain forms of joint ownership among insurers, PBMs, wholesalers, and medical providers, require companies to come into compliance within one year, and impose penalties for violations. It would also grant enforcement authority to federal and state regulators and allow review of future transactions that could recreate prohibited conflicts of interest. Proponents cite precedents in other industries where structural separation has been used to promote competition and consumer protection and describe the legislation as an effort to address perceived conflicts of interest within the current health care marketplace.